DS Research is actively participating as a clinical trial site in the ongoing Phase 3 development program for envudeucitinib, an investigational oral TYK2 inhibitor showing strong potential in the treatment of moderate-to-severe plaque psoriasis.
As innovation in plaque psoriasis treatment continues to accelerate, DS Research is proud to support research that is shaping the future of dermatology care. Alumis Inc. recently announced positive Phase 3 results for envudeucitinib, highlighting early and robust improvements in patients with moderate-to-severe plaque psoriasis.
Read the full press release:
https://investors.alumis.com/
Advancing a Next-Generation Oral Therapy
Envudeucitinib is part of a new class of therapies known as TYK2 inhibitors, which are designed to selectively target pathways involved in immune-mediated inflammation.
By modulating cytokines such as IL-23 and IL-12, this investigational therapy aims to:
- Deliver strong clinical efficacy
- Maintain a favorable safety profile
- Provide a convenient oral alternative to injectable treatments
As an oral therapy, envudeucitinib represents an important step forward in expanding treatment options for patients living with plaque psoriasis.
Ongoing Phase 3 Trial Progress and Promising Results
The Phase 3 ONWARD clinical program (ONWARD1 and ONWARD2) continues to evaluate envudeucitinib across diverse patient populations.
To date, reported results demonstrate:
- Rapid and statistically significant improvements in skin clearance
- High rates of PASI 90 (near-complete skin clearance)
- Meaningful achievement of PASI 100 (complete clearance)
- Consistent efficacy across study populations
- Favorable safety and tolerability profile
These early findings highlight the potential of envudeucitinib to deliver meaningful clinical benefit, while ongoing study participation continues to generate important long-term data.
DS Research’s Role Across Kentucky and Indiana
DS Research is actively enrolling and supporting patients in this ongoing clinical trial at sites across Kentucky and Indiana.
As a participating clinical research site, our team is responsible for:
- Patient recruitment and engagement
- Study execution in accordance with FDA and GCP standards
- Ongoing monitoring of safety and outcomes
- High-quality data collection to support regulatory evaluation
Our involvement reflects DS Research’s strong presence in dermatology clinical trials in Kentucky and Indiana and our commitment to advancing innovative therapies for patients in our communities.
Why Ongoing Clinical Trials Matter
Active participation in Phase 3 trials is critical to ensuring that investigational therapies are thoroughly evaluated before potential regulatory approval.
Ongoing studies like the ONWARD program help to:
- Confirm long-term safety and tolerability
- Validate effectiveness across broader populations
- Expand access to emerging therapies for patients today
Through continued participation, DS Research helps bring cutting-edge treatments closer to real-world use.
Shaping the Future of Psoriasis Treatment
Envudeucitinib reflects a broader shift toward targeted oral therapies in dermatology and immune-mediated diseases. As data continues to emerge, this investigational therapy may play a meaningful role in the future treatment landscape for plaque psoriasis.
For patients, this evolution may lead to:
- More convenient, non-injectable treatment options
- Greater flexibility in care
- Improved long-term disease management
Contact DS Research
DS Research is proud to support ongoing clinical trials that advance the future of dermatology care.
If you are:
- A biopharmaceutical sponsor seeking an experienced clinical trial site in Kentucky or Indiana
- A patient interested in participating in a psoriasis clinical trial
- A provider looking to collaborate on research
Contact DS Research today to learn more about our clinical trial opportunities and active studies.
